Haleos Share Price Today

Haleos Labs shareholders approve all resolutions at 20th AGM

Haleos Labs held its 20th AGM on September 30, 2026, via video conferencing. All eight resolutions passed with requisite majority, including dividend declaration. Promoter votes excluded from two resolutions due to interest conflict. Total valid votes polled for standard resolutions stood at 23,68,751.

Haleos Labs provides weblink for AGM notice to shareholders without email

Haleos Labs provides weblink and QR code for Annual Report 2025-26 and AGM notice to shareholders without registered emails. The 20th AGM is scheduled for September 30, 2026, with e-voting from September 26 to September 29. Record date for FY26 dividend and voting rights is fixed for September 23, 2026. Shareholders are urged to update KYC details with DPs or RTA to receive future communications electronically.

Haleos Labs shareholders reject executive pay resolution in postal ballot

Shareholders approved Mrs. Sudeepthi Gopineedi's reappointment as WTD with 99.99% support. Special resolution for managerial remuneration failed with 82.16% votes against it. Promoter group cast 4,83,612 valid votes against the remuneration proposal. Related party transactions for FY27 were approved with near-unanimous public support.

Haleos Labs declares ₹1.50 per share final dividend for FY26

Haleos Labs recommends a final dividend of ₹1.50 per share for FY26. The payout is subject to approval at the upcoming Annual General Meeting. Record date is fixed for September 23, 2026. Shareholders must submit tax declarations by September 25, 2026. TDS rates vary from nil to 20% plus surcharge based on category.

Haleos Labs' Material Subsidiary Mahi Drugs Appoints Vincent P. Asaro as Nominee Director, Names New Cost Auditors

Mahi Drugs Private Limited, a material subsidiary of Haleos Labs Limited (formerly SMS Lifesciences India Limited), at its Board meeting on August 5, 2026, appointed Mr. Vincent P. Asaro (DIN: 11827706), President of ChemWerth Inc. and a US citizen with over 35 years of industry experience, as Nominee Director in place of Mr. M. Madhu Rao. The Board also appointed Annapragada & Co. (FRN: 0060311) as Cost Auditors for the financial year 2026-27, with remuneration subject to shareholder ratification at the next Annual General Meeting. Both appointments were disclosed to stock exchanges pursuant to Regulation 30(9) of the SEBI (LODR) Regulations, 2015.

Haleos Labs reappoints Mannam Malakondaiah and Srinivas Samavedam as directors

Haleos Labs Limited reappoints Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam as independent directors for a five-year term starting November 13, 2026. The Board approved the move on August 5, 2026, citing their expertise in public administration and healthcare. Shareholder approval is required for the appointments to take effect.